secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atea Pharmaceuticals, Inc. (AVIR)
CIK:        0001593899
Form:       8-K
Filed at:   2025-03-06T23:59:59+00:00
Accession:  0001193125-25-048426
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atea reports Q4/FY2024 results; cash at $454.7M; HCV Phase 3 starts April 2025
------------------------------------------------------------------------------

- Net loss per share Q4 2024 improved to ($0.40) from ($0.47); full year net loss per share ($2.00) vs ($1.63).
- Cash, cash equivalents and marketable securities $454.7M at Dec 31, 2024 vs $578.1M year earlier.
- Successful End-of-Phase 2 FDA meeting for HCV regimen bemnifosbuvir/ruzasvir; Phase 3 enrollment expected April 2025.
- Reduced workforce by 25% in Q1 2025 to achieve ~$15M in cost savings through 2027.
- Engaged Evercore for strategic partnerships for HCV Phase 3 program; appointed Arthur S. Kirsch to board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1593899/000119312525048426/0001193125-25-048426-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1593899/000119312525048426/d925111d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-048426

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer